Cardiac surgery in the heart transplant recipient

• Verfasst von: Farag, Mina [VerfasserIn]
• Verfasst von: Arif, Rawa [VerfasserIn]
• Verfasst von: Raake, Philip [VerfasserIn]
• Verfasst von: Kreußer, Michael [VerfasserIn]
• Verfasst von: Karck, Matthias [VerfasserIn]
• Verfasst von: Ruhparwar, Arjang [VerfasserIn]
• Verfasst von: Schmack, Bastian [VerfasserIn]
• Titel: Cardiac surgery in the heart transplant recipient
• Titelzusatz: outcome analysis and long-term results
• Verf.angabe: Mina Farag, Rawa Arif, Philip Raake, Michael Kreusser, Matthias Karck, Arjang Ruhparwar, Bastian Schmack
• E-Jahr: 2019
• Jahr: 12 September 2019
• Umfang: 6 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 10.01.2020
• Titel Quelle: Enthalten in: Clinical transplantation
• Ort Quelle: Oxford [u.] : Wiley-Blackwell, 1999
• Jahr Quelle: 2019
• Band/Heft Quelle: 33(2019), 10 vom: Okt., Artikel-ID e13709, Seite 1-6
• ISSN Quelle: 1399-0012
• DOI: doi:10.1111/ctr.13709
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: heart transplant
• Sach-SW: outcome analysis
• Sach-SW: repeat surgery
• K10plus-PPN: 1687138184
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Background Survival rates following cardiac transplantation continue to improve. Due to the scarcity of available organs, extended donor criteria have become more prevalent in clinical practice. In this context, the risk of developing cardiac pathology requiring surgical correction is increasing. Methods Between January 1991 and October 2010, a total of 479 patients received cardiac transplantations at the University Hospital Heidelberg. Of those, 18 (3.8%) patients required subsequent cardiac surgery until 2018. Short- and long-term analyses were performed. Results Indications for cardiac surgery included valvular disease (n = 16) with the majority of cases affecting the tricuspid valve (n = 10), while 6 patients received mitral valve surgery, of whom 3 patients underwent concomitant valve surgery. Other indications included CABG (n = 1) and re-transplantation (n = 1) for allograft dysfunction. Mean follow-up time was 6.5 years, while mean interval to surgery was 6.0 years. Early mortality was 11.1% (n = 2), while overall survival at 1, 5, and 10 years were, 88.1%, 81.4%, and 52.2%, respectively. Compared to an overall survival of that transplant cohort at 1, 5, and 10 years of 76.7%, 66.7%, and 52.4% percent, respectively (P = .271). Conclusion According to our data, redo cardiac surgery can be performed with acceptable mortality and morbidity. Atrioventricular valve pathology plays a chief role in these patients.